DeCell Technologies Incorporated
$50,000.00 CAD
≈ 8 months of average Canadian pay
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2018-2019
- Agreement period
- January 3, 2019 – April 19, 2019
- Reference
- nrc-cnrc:172-2018-2019-Q4-918410
Published purpose
DermGEN™ has been developed as a novel decellularized allograft for the wound care market and is poised to commence commercial sales. DeCell Technologies proposal is to automate the decellularization process, using a closed system, dramatically reducing risks of contamination. Full automation of such a system has not been achieved by competing products, and would significantly differentiate DeCell Technologies platform from the competition as well as providing a significant cost advantage.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.
Good value
Local impact
Needs context
Questionable
Success story
Wasteful
View official source record
Imported July 30, 2026 from open.canada.ca Grants & Contributions